LPTX Leap Therapeutics, Inc.
Healthcare$0.77-3.15%ClosedMarket Cap: $31.9M
As of 2026-05-26
Valuation
P/E (TTM)
6.61
PEG
0.06
P/B
2.39
P/S
0.00
EV/EBITDA
-2.07
DCF Value
$2.17
FCF Yield
-63.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.9%
ROA
-65.1%
ROIC
-35.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-4.8M | $-77.2M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.1M | $62.9M | $— | — |
| FY null | $0.00 | NaN% | $-36.5M | $4.8M | $— | — |
| Q3 null | $209.0K | -9631.6% | $-3.2M | $-26.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-16.9M | $-16.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.9M | $-15.4M | $— | — |
| Q4 null | $234.0K | -4461.5% | $-45.0M | $-40.2M | $— | — |
| FY null | $0.00 | NaN% | $-70.1M | $-67.6M | $— | — |
| Q3 null | $0.00 | NaN% | $-17.9M | $-18.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-21.3M | $-20.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-14.8M | $-13.8M | $— | — |
| Q4 2023 | $337.0K | -1713.6% | $-11.7M | $-24.7M | $-0.46 | — |